Skip to main content

Quality of Harmonized Drug Substance Dossier for a Marketing Authorization

BayBiotech.NET

Through the ICH process (ICH M4Q), considerable harmonization has been achieved among the three regions (Japan, EU and US) in the technical requirements for the registration of pharmaceuticals for human use. To avoid the need to generate and compile different registration dossiers, the ICH: M4 guideline describes a format for the Common Technical Document that will be acceptable in all three regions.

In a nutshell, CTD is an internationally agreed upon format for the preparation of a presentation for applications to be submitted to the regulatory authorities. However, the CTD does not address the content of submissions. There are many regional requirements, as well as applicants’ preferences, that could affect the contents of dossiers submitted in each region.

According to the ICH guidelines, a document is defined for a paper submission as a set of pages, numbered sequentially and divided from other documents by a tab and a document can be equated to a file for an electronic submission. In an electronic submission, a new file starts at the same point at which in a paper submission, a tab divides the documents.
In deciding whether one or more documents or files are appropriate, it should be considered that once a particular approach has been adopted, the same approach should be used throughout the life of the dossier since it is the intention that replacement documents/files be provided when information is changed.

It is recommended that all the text and tables should be prepared using margins that allow the document to be printed on A4 paper (EU and Japan) and 8.5x11” paper (USA). Times New Roman, 12-point font is recommended for narrative text.

For more details follow the link: ICH M4Q Guideline Common Technical Document for the Registration of Pharmaceuticals for Human use, Quality

Comments

Post a Comment

Popular posts from this blog

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...
Post a Comment
Read more